Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Results of Operations and Financial Condition

Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On March 15, 2017, Voyager Therapeutics, Inc. (the Company)
announced financial results for the quarterand year ended
December 31, 2016. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:

Mar

Exhibit No.

Description

99.1

Press release datedMarch 15, 2017 entitled Voyager
Therapeutics Reports Fourth Quarter and Full Year 2016
Financial Results and Corporate Highlights

2


About Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson’s Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich’s Ataxia, VY-HTT01 for Huntington’s Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Recent Trading Information

Voyager Therapeutics, Inc. (NASDAQ:VYGR) closed its last trading session down -0.36 at 11.49 with 68,747 shares trading hands.

An ad to help with our costs